We are delighted to confirm that we will be presenting a poster session at this year’s American Association for Cancer Research conference, which runs from 25 to 30 April. We’ll be revealing details of our pancEpi1Dx PCR assay; a simple, cost efficient and highly sensitive test for the early detection of pancreatic cancer.
Pancreatic cancer remains the most lethal malignancy due to its clinical silent and aggressive nature. Due to the lack of early diagnosis and effective screening tools, the majority of pancreatic cancer patients are diagnosed at an advanced stage when surgery is no longer feasible. The five-year survival rate of pancreatic cancer is less than 5%.
At AACR we’ll be talking about how Epi One has identified molecular biomarkers for early detection of pancreatic cancer with unprecedented accuracy. CEO Michael Marquardt says: “I’m very much looking forward to sharing a first look ‘under the hood’ of our groundbreaking scientific approach at one of the world’s largest cancer research conferences.”
